Linda Schumacher Feero, MD
Ophthalmology · Augusta, MENPI 1821064023
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 24.0% of the total. 2025 is the largest year on record at $495, 3.9 times the $125 reported in 2019.
Across 59 payments — averaging $26.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$371
- Lumenis BE Inc$321
- Oyster Point Pharma, Inc.$145
- Amgen$142
- Novartis$106
- Alcon$100
- plus $359 from 9 others
What the payments were for
- Food & beverage$1,48396%
- Gifts$453%
- Entertainment$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $371 |
| Lumenis BE Inc | 1 | $321 |
| Oyster Point Pharma, Inc. | 4 | $145 |
| Amgen(2 entities) | 7 | $142 |
| Novartis | 6 | $106 |
| Alcon | 5 | $100 |
| Sun Pharmaceutical Industries Inc. | 6 | $99 |
| Aerie Pharmaceuticals, Inc. | 3 | $57 |
| Tarsus Pharmaceuticals, Inc. | 3 | $49 |
| Bausch & Lomb Americas Inc. | 2 | $43 |
| Dompe US, Inc. | 2 | $38 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Optos, Inc. | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,545 in reported general payments places this provider in the 80th percentile of 74 ophthalmology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 132 | $183,735 |
| XdemvyLotilaner | 49 | $97,536 |
| XiidraLifitegrast | 63 | $86,962 |
| MieboPerfluorohexyloctane/Pf | 31 | $40,806 |
| Fluorometholone | 232 | $26,393 |
| VyzultaLatanoprostene Bunod | 34 | $20,215 |
| Loteprednol Etabonate | 94 | $15,510 |
| LumiganBimatoprost | 17 | $10,010 |
| TyrvayaVarenicline Tartrate | 11 | $9,469 |
| Cyclosporine | 23 | $8,030 |
| MoxifloxacinMoxifloxacin Hcl | 280 | $6,852 |
| IlevroNepafenac | 11 | $4,049 |
| Travoprost | 18 | $1,728 |
| Prednisolone Acetate | 33 | $1,260 |
| Latanoprost | 71 | $977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $371 | $193,744149 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $43 | $147,984128 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $49 | $97,53649 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $145 | $9,46911 claims |
| NovartisIlevro | $106 | $4,04911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 74 ophthalmology providers in Maine.
Other ophthalmology in Augusta
- Maroulla GleatonAugusta$1K
- Charles ZacksPortland$36K
- Martin WhitakerNorway$5K
- Hallie HahnPortland$5K
- Curt YoungBangor$5K
- Samuel SolishPortland$4K
- Ravindra ShahPortland$4K
- Richard FrancePortland$4K
- Cynthia SelfBangor$3K
- Tamzid RahmanPortland$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.